Research graph
References from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells. Local targets link to admitted publications; unresolved targets remain external evidence.
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
10.1182/blood-2011-10-384388 · 2012 · External reference
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
10.1056/nejmoa1709866 · 2018 · External reference
Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
10.1056/nejmoa1707447 · 2017 · External reference
Innovation and opportunity for chimeric antigen receptor targeted T cells
10.1016/j.jcyt.2013.02.007 · 2013 · External reference
Chimeric antigen receptor T cells in refractory B-cell lymphomas
10.1056/nejmoa1708566 · 2017 · External reference
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
10.1016/j.bbmt.2018.12.758 · 2019 · External reference
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
10.1007/s00281-024-01013-w · 2024 · External reference
Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies
10.1073/pnas.1307309110 · 2013 · External reference
Development of a high affinity, non-covalent biologic to add functionality to Fabs
10.1038/srep07817 · 2015 · External reference
Engineering a high-affinity peptide binding site into the anti-CEA mAb M5A
10.1093/protein/gzx016 · 2017 · External reference
Design of HIV vectors for efficient gene delivery into human hematopoietic cells
10.1006/mthe.2002.0558 · 2002 · External reference
Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2+ breast cancer metastasis to the brain
10.1158/1078-0432.ccr-17-2041 · 2018 · External reference
Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer
10.1080/2162402x.2017.1380764 · 2018 · External reference
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies
10.1016/j.ccr.2011.09.003 · 2011 · External reference
Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy
10.1038/mt.2014.208 · 2015 · External reference
Optimization of IL13Rα2-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma
10.1016/j.ymthe.2017.10.002 · 2018 · External reference
Albumin binding as a general strategy for improving the pharmacokinetics of proteins
10.1074/jbc.m205854200 · 2002 · External reference
Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity
10.1172/jci.insight.99048 · 2018 · External reference
Glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis
10.1371/journal.pone.0077769 · 2013 · External reference
An improved single-chain Fab platform for efficient display and recombinant expression
10.1016/j.jmb.2014.11.017 · 2015 · External reference
10.1016/j.bneo.2024.100048 · 2024 · Admitted local publication
A CAR RNA FISH assay to study functional and spatial heterogeneity of chimeric antigen receptor T cells in tissue
10.1038/s41598-021-92196-x · 2021 · External reference
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
10.1182/blood-2011-04-348540 · 2011 · External reference
Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation tolerance
10.1172/jci139991 · 2021 · External reference
A CAR enhancer increases the activity and persistence of CAR T cells
10.1038/s41587-024-02339-4 · 2025 · External reference
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
10.1126/science.aar3246 · 2018 · External reference
IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM
10.1136/jitc-2022-006239 · 2023 · External reference
IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype
10.1158/2326-6066.cir-18-0466 · 2019 · External reference
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}
10.1073/pnas.0600240103 · 2006 · External reference
IL-15 superagonist-mediated immunotoxicity: role of NK cells and IFN-γ
10.4049/jimmunol.1500300 · 2015 · External reference
Chimeric antigen receptor T cells for sustained remissions in leukemia
10.1056/nejmoa1407222 · 2014 · External reference
The immune epitope database (IEDB): 2024 update
10.1093/nar/gkae1092 · 2025 · External reference
Universal chimeric antigen receptors for multiplexed and logical control of T cell responses
10.1016/j.cell.2018.03.038 · 2018 · External reference
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
10.1016/s0140-6736(14)61403-3 · 2015 · External reference
Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia
10.1056/nejmoa1709919 · 2018 · External reference
Metabolic programming and immune suppression in the tumor microenvironment
10.1016/j.ccell.2023.01.009 · 2023 · External reference
The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth
10.1016/j.ccell.2023.02.016 · 2023 · External reference
Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18
10.1016/j.celrep.2017.09.002 · 2017 · External reference
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
10.1038/s41598-017-10940-8 · 2017 · External reference
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
10.1038/s41586-024-08261-8 · 2025 · External reference
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial
10.1038/s41591-025-03745-0 · 2025 · External reference
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
10.1038/nm.4441 · 2018 · External reference
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
10.1038/s41591-021-01436-0 · 2021 · External reference
CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia
10.1038/s41375-021-01477-x · 2022 · External reference
T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells
10.1158/2326-6066.cir-15-0231 · 2016 · External reference
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
10.1038/s41467-020-16160-5 · 2020 · External reference
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
10.1038/s41591-020-1081-3 · 2020 · External reference
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
10.1172/jci83416 · 2016 · External reference
Sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells for adult patients with refractory/relapsed B-cell acute lymphoblastic leukemia
10.1182/blood.v130.suppl_1.846.846 · 2017 · External reference
Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells
10.1136/jitc-2021-003752 · 2022 · External reference
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
10.1073/pnas.1524155113 · 2016 · External reference
A universal chimeric antigen receptor (CAR)-fragment antibody binder (FAB) split system for cancer immunotherapy
10.1126/sciadv.adv4937 · 2025 · External reference
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML
10.1182/blood.2020009759 · 2021 · External reference
Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory
10.1073/pnas.1810060115 · 2018 · External reference
convertibleCARs: a chimeric antigen receptor system for flexible control of activity and antigen targeting
10.1038/s42003-020-1021-2 · 2020 · External reference
